Stephens Inc. AR Sells 5,458 Shares of Neogen Co. (NASDAQ:NEOG)

Stephens Inc. AR decreased its position in Neogen Co. (NASDAQ:NEOG) by 15.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 30,472 shares of the company’s stock after selling 5,458 shares during the quarter. Stephens Inc. AR’s holdings in Neogen were worth $370,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in NEOG. Allspring Global Investments Holdings LLC grew its holdings in shares of Neogen by 142.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after purchasing an additional 1,165 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Neogen by 196.7% in the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after purchasing an additional 2,233 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Neogen in the 3rd quarter worth about $66,000. KBC Group NV grew its holdings in shares of Neogen by 39.1% in the 4th quarter. KBC Group NV now owns 8,464 shares of the company’s stock worth $103,000 after purchasing an additional 2,379 shares during the last quarter. Finally, Marco Investment Management LLC bought a new stake in shares of Neogen in the 3rd quarter worth about $169,000. Institutional investors own 96.73% of the company’s stock.

Neogen Stock Down 0.9 %

Shares of NASDAQ:NEOG opened at $9.83 on Friday. Neogen Co. has a 12 month low of $9.70 and a 12 month high of $18.58. The company’s 50-day moving average price is $11.78 and its two-hundred day moving average price is $14.19. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. The firm has a market cap of $2.13 billion, a P/E ratio of -4.49 and a beta of 1.23.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Friday, January 10th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The firm had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. During the same quarter in the prior year, the firm earned $0.11 EPS. The company’s revenue was up .7% on a year-over-year basis. As a group, research analysts forecast that Neogen Co. will post 0.38 EPS for the current fiscal year.

Insider Buying and Selling at Neogen

In other Neogen news, CEO John Edward Adent bought 23,035 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were bought at an average cost of $11.03 per share, for a total transaction of $254,076.05. Following the transaction, the chief executive officer now owns 269,164 shares in the company, valued at approximately $2,968,878.92. This trade represents a 9.36 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO David H. Naemura bought 14,800 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were acquired at an average price of $11.11 per share, for a total transaction of $164,428.00. Following the completion of the transaction, the chief financial officer now owns 61,434 shares in the company, valued at approximately $682,531.74. This trade represents a 31.74 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.13% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on NEOG. Piper Sandler reaffirmed a “neutral” rating and issued a $13.00 target price (down previously from $16.50) on shares of Neogen in a report on Tuesday, January 21st. Guggenheim started coverage on shares of Neogen in a report on Thursday, December 19th. They set a “buy” rating and a $15.00 price objective on the stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.